To further confirm the roles of LATS1 and LATS2 in human CML cells, shRNA targeting LATS1 and LATS2 was used to generate the LATS1/2—knockdown (KD)—K562 cell line. This evidence concerns the gene LATS2 and chronic myelogenous leukemia, BCR-ABL1 positive.